Burroughs Wellcome Retrovir
Executive Summary
Temporary distribution system, set up initially to ensure that the limited supply of AZT would reach target population of AIDS and advanced ARC patients, will be discontinued ahead of schedule. At the time of the drug's approval in March, Burroughs Wellcome said it would dissolve the elaborate distribution system once the company had enough drug to meet demand. Last spring, B-W predicted supply levels would not reach enough for 30,000 patients until year end; however, the company now says it can treat 50,000 patients.
You may also be interested in...
Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
Biotin And ‘Healthy Hair’: Federal Pre-emption Clips False Advertising Complaint In California
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: